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ABSTRACT 
Objective: Although the effectiveness of many psychosocial interventions for people with 
cancer has been established, one barrier to implementation in routine clinical care is a lack of 
data on cost-effectiveness. We conducted a systematic review to assess the cost-effectiveness 
of psychosocial interventions for improving psychological adjustment among people with 
cancer.  
Methods: Systematic review of the literature, study appraisal, and narrative synthesis.  
Results: Eight studies involving 1,668 patients were identified. Four of these reported 
outcomes in a cost per quality adjusted life year (QALY) framework. Six studies reported 
psychosocial interventions to be cost-effective for improving health-related quality of life, 
mood, pain, distress, or fear of cancer progression, compared to usual care. Of the six 
psychosocial interventions identified as cost-effective, three were cognitive behavioural 
therapy based interventions, one was a nurse-delivered telephone follow-up plus educational 
group program, one was a group-based exercise and psychosocial intervention, and one was a 
series of 10 face-to-face or telephone-based individual support sessions delivered by a nurse. 
The quality of studies according to the CHEC-list criteria was good overall; however, some 
studies were limited by their choice of outcome measure and omission of important 
categories of costs.  
Conclusions: Several psychosocial interventions, particularly those based on cognitive 
behavioural therapy, have been demonstrated to represent good value for money in cancer 
care. Future research should include a clear definition of the economic question, inclusion of 
all relevant costs, and consideration of utility-based quality of life measures for QALY 
estimation.  
Systematic review registration: PROSPERO Registration Number: CRD42014006370. 
Keywords: Psychosocial, cost-effectiveness, economic evaluation, cancer, quality of life 
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Background 
Due to the increasing incidence of and survival from cancer, the psychological burden of 
cancer continues to rise. One-third of cancer patients experience severe psychological distress 
and up to 70% will experience some level of anxiety or depression [1, 2]. How well patients 
live (i.e. quality of life) has long been recognised as important as how long they live (i.e. 
survival time) [3, 4]. Therefore identification and management of psychological difficulties in 
people with, or who have survived cancer is an essential part of comprehensive cancer 
care [5]. 
Several reviews and meta-analyses have examined the effectiveness of psychosocial 
interventions for the management of psychological difficulties experienced by cancer 
patients  [3, 6-10]. A meta-analysis by Meyer and Mark  [7] found that relaxation and 
behavioural modification improved functional adaptation and symptom control. Psychosocial 
interventions have also been used to manage depression in cancer patients. Two systematic 
reviews [6]  [3] reported that psychosocial interventions were effective in improving 
depression. Moreover, people with cancer who take part in psychosocial interventions have 
been shown to report lower level of depression and anxiety, and improved quality of 
life [8]   [9]. 
Although the effectiveness of a range of psychosocial interventions for people with cancer 
has been established, one barrier to their implementation in routine clinical care is a lack of 
data on their cost-effectiveness. Given the scarcity of healthcare resources and the 
increasingly tight funding of healthcare systems, it is vital that psychosocial interventions be 
evaluated not only in terms of efficacy in symptom reduction, but in economic terms as 
well [11]. It is important to consider whether conducting psychosocial interventions are 
worthwhile given the incremental costs and incremental benefits they may generate. A cost-
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effective intervention is one that represents good value for money, supporting the additional 
investment it may require, or the diversion of resources from less effective alternatives. A 
cost-effective intervention is not necessarily cost-saving, but usually achieves greater benefit 
than its comparator. The additional cost per health outcome that is considered “worthwhile” 
is based on explicit or arbitrary willingness to pay thresholds as well as other key criteria, 
usually defined by government decision makers [12]. In the United States, an intervention is 
generally considered cost-effective compared to the next best alternative if it costs below 
US$50,000 per QALY gained [13].  In Australia, although there is not an explicit threshold 
value, an observation of the decisions of the Pharmaceutical Benefits Advisory Committee 
between 1994 and 2003 point to a threshold of AU$69,900 per QALY gained [14], while in 
the UK it is between £20,000-£30,000 per QALY [15]. 
 
In 2004, Carlson and Bultz reported that many psychosocial interventions for cancer resulted 
in a reduction of subsequent healthcare use and savings in medical expenditure, particularly 
related to ongoing treatment for depression [11]. In 2011, Gordon et al. [16] published a 
review investigating the cost-effectiveness of interventions specifically designed to treat 
depression and anxiety in cancer patients.  This review was not able to make a firm 
recommendation about whether particular types of interventions were cost-effective, possibly 
due to a small number of relevant studies. Thus, the aim of the present review was to 
systematically search the literature to assess the total costs and health benefits of 
psychosocial interventions for all types of psychological conditions in people with cancer, 
compared to usual care, from either a societal or health system perspective. 
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Methods 
The protocol for this review was registered in the PROSPERO register (Registration number: 
CRD42014006370; http://www.crd.york.ac.uk/PROSPERO) in January 2014. The preferred 
reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [17] were 
followed to identify and screen publications, extract data, and describe the systematic review 
process. 
 
Inclusion criteria 
Economic evaluations based on psychosocial interventions aiming to improve quality of life 
and/or psychological outcomes for people with, or survivors of, cancer were included. We 
included all economic evaluation study types that aggregated monetary costs and 
psychological health outcomes. The total cost will take into account the costs of the 
intervention plus the costs of downstream care as the result of an intervention. Economic 
evaluations are comparative analyses of alternative interventions in regards to costs, resource 
use, and health outcomes [18]. There are three main types of full economic evaluations and 
they differ in the approach taken to measure the health benefits of the intervention. Cost-
effectiveness analysis measures costs and benefits of interventions with costs expressed in 
monetary units (e.g. $) and effects in clinical outcome units (e.g. years of life); cost-utility 
analysis measures costs in monetary units and benefits in Quality Adjusted Life Years 
(QALYs); cost-benefit analysis measures costs and benefits with both expressed in monetary 
units. 
 
Exclusion criteria 
We excluded: 
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 Cost consequence studies, where costs and effects were presented in a 
disaggregated format; 
 Studies that assessed costs only and included no measures of benefits; 
 Studies that made claims of cost-effectiveness but did not quantify or report 
cost and effectiveness outcomes;  
 Methodological papers that did not present health economic outcomes; 
 Review articles and case studies; 
 Commentaries, letters, editorials, and conference abstracts; and 
 Studies not published in a peer-reviewed journal. 
 
Search strategy 
Relevant international electronic bibliographic databases were searched from 1980 to May 
2015, including Medline, Medline In-Process, Embase, PsycINFO, Cumulative Index to 
Nursing and Allied Health Literature (CINHAL), Econlit, Cost Effectiveness Analysis 
Registry (CEA Tufts), and the National Health Service Economic Evaluation Database (NHS 
EED). We also searched the reference lists of retrieved publications to identify any additional 
relevant articles. Medical Subject Heading (MeSH) terms and text words for the population 
(cancer, neoplasms), the intervention (cognitive and behavioural intervention, psychotherapy, 
cognitive therapy, psycho-education, psychosocial), and the outcomes or study design 
(Quality-Adjusted Life Years, cost, Cost-Benefit Analysis, cost-effectiveness, cost utility, 
economic evaluation) were combined. Supplementary Table 1 shows the search strategy used 
for Medline. The search strategies for other databases were similar but tailored slightly to fit 
each specific database. Auto-alerts were installed to provide continual literature updates. 
Study Selection 
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The first  author (MD) screened all manuscripts, titles and abstracts for non-research articles, 
duplicates and irrelevant references, such as single case reports, letters, commentaries, 
conference abstracts, or those focused on clinical issues. Then the selected, screened 
manuscripts were fully assessed by two reviewers (MD, RM). Disagreement was resolved 
through discussion until a consensus was reached. We extracted the following information 
using a predefined data form: study location, publication year, type of cancer, type of 
psychosocial intervention, type of economic evaluation (i.e. cost-effectiveness, cost-utility or 
cost–benefit analysis), economic evaluation methods used (e.g. modelled or within-trial 
analysis), perspective of analysis (health system or societal), time horizon of analysis, 
reference year for costs, discount rate (i.e. the rate of adjustment of the value of costs or 
benefits that occur at different points of time in the future) [19], psychological outcomes, 
quality of life, QALYs, survival, costs included, incremental cost effectiveness ratios 
(ICERs) or net benefit reported; and type of sensitivity analysis conducted. “Traditional 
techniques of meta-analysis are not appropriate for pooling results of many economic 
analyses because of the different outcome measures used, multiple country perspectives, 
different interventions and comparators.” 
 
Costs in economic evaluations of health care interventions can be divided into direct medical 
costs, direct non-medical costs, and indirect non-medical costs [20]. Direct medical costs 
refer to medical costs borne by patients and payers as a consequence of disease, intervention, 
side effects (e.g. drug costs, costs of healthcare personnel, hospital costs) [20]. Direct non-
medical costs refer to costs that accrue to patients and their families while receiving health 
care (e.g. travelling to hospital for treatment) [20]. Indirect non-medical costs refer to costs 
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indirectly associated with the illness or the intervention of interest (e.g. family caregiver time, 
lost work time) [20]. 
 
Appraisal and Quality Assessment 
Traditional techniques of meta-analysis are not appropriate for pooling results of many 
economic analyses because of the different outcome measures used and multiple country 
perspectives [21]. For this reason, we used a narrative approach to summarise the findings as 
recommended by the Campbell and Cochrane Economics Methods Group [22]. We also 
constructed a permutation matrix  [23] to categorise the cost-effectiveness results to inform 
decision making. The methodological quality and risk of bias of the included studies were 
assessed using the Consensus Health Economic Criteria (CHEC) list [24]. The CHEC-list is 
suitable for evaluating within-trial economic evaluations [24], and consists of 19 yes-or-no 
questions. Two authors (MD and RM) used the CHEC-list to independently assess the quality 
of each individual study with a consensus reached through discussion. 
 
Results 
Literature search 
Results of the literature search are summarised in Figure 1. The initial search yielded 2,083 
records; after removing duplicates and applying the inclusion and exclusion criteria to the 
titles and abstracts, 22 articles remained. After assessment of the full text, eight economic 
evaluations of psychosocial interventions for cancer care were included in this review (see 
Table 1). Supplementary Table 2 lists the 14 excluded studies along with the reasons for their 
exclusion.  
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Of the eight identified studies, two were undertaken in the USA [25, 26], and one each from 
Australia [27], the United Kingdom [28], Canada [29], Sweden [30], the Netherlands [31] 
and Germany [32]. Five studies [26, 27, 29-31] were undertaken with breast cancer patients, 
two among people with a range of cancers  [32]  [28], and one with melanoma patients [25]. 
Of the 12 interventions tested in the eight studies reviewed, half (6) were individual therapies 
and half tested the effect of group-based therapies. 
 
 
Study Design 
All eight included studies were within-trial economic evaluations, where economic data (e.g. 
resource utilisation, quality of life) were collected alongside a single clinical study, usually a 
controlled clinical trial [33]. Five studies were two-arm randomised controlled trials 
(RCT) [25, 28-30, 32], two studies [26, 30] were three-arm RCTs, and one study by Kimman 
et. al was a four-arm RCT [31]. Five of the studies had usual care as the comparator [25, 28-
31]; whereas Sabriego et al.  [32] used another psychosocial intervention as the comparator, 
Mandelblatt and colleagues  [26] used an information booklet as the comparator, and Gordon 
et al.  [27] chose an external comparator sample from another study concurrently undertaken 
at the same university. Five of the studies were cost-effectiveness analyses (CEA) [25-27, 31, 
32], two studies performed cost-utility analyses (CUA)  [28, 30], and one undertook both cost 
minimisation and cost-effectiveness analyses [29]. Half of the studies  [25, 29, 30, 32] stated 
the reasons for choice of study type. The sample size of the economic evaluations ranged 
from 30 to 389 participants. The majority of the studies were not powered to detect a 
difference in cost-effectiveness, as power calculations had been based on the primary clinical 
outcome [25, 28-30, 32]. Three studies did not include information on sample size 
10 
 
calculations [26, 27, 31]. The follow-up period ranged from 6 to 24 months, with only one 
study [30] including a two-year follow-up.  
  
Costs 
Four studies were conducted from a societal perspective  [26, 27, 31, 32] and four from a 
healthcare system perspective [25, 28-30]. None of the studies included a discussion of the 
rationale for the choice of perspective. Resource use and unit costs were reported by five of 
the studies [25-27, 31, 32]. Three studies reported mean costs only [28-30] (Table 1). 
 
Direct medical costs 
All studies reported direct medical costs, including treatment costs, outpatient hospital visits, 
and hospitalisation costs (Table 2). For all studies, direct medical costs were estimated from 
self-reported healthcare services use, hospital records and medical databases. All studies 
calculated costs related to the intervention and presented costs separately for the intervention 
and comparator(s). In one study  [30], the intervention costs comprised 3% of total costs. 
Despite that intervention costs, the total health care costs were lower in the intervention 
groups than in the usual care group. The authors concluded that unmet psychological needs in 
the usual care group resulted in additional healthcare resource use. 
 
One study  [27] found that health service expenditure was higher in the psychosocial 
intervention (STRETCH) group. One study  [31], on the other hand, found that participation 
in a nurse-led intervention was associated with fewer hospital follow-up visits, laboratory 
tests, other diagnostics, and fewer contacts with specialised health professionals. Contrary to 
their expectation, one study  [29], found that radiation and psychotropic drug utilisation was 
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significantly higher in the intervention arm. One study  [26] were not able to show that an 
effective intervention for meeting patient needs (i.e. improvement in distress) would decrease 
direct medical costs. One study  [32] reported that patients in the intervention group had 
fewer general practice visits and inpatient days, and less outpatient treatment in hospital, 
which resulted in lower direct medical costs at 12 months. One study  [28] reported that 
patients in the intervention group had a moderate incremental per patient cost for healthcare 
costs and antidepressant medication compared to the usual care group. Bares et al. [25] 
reported direct medical costs of the psychosocial intervention (i.e. cognitive behavioural 
therapy), but not the subsequent cost of healthcare. (Table 2) 
 
Direct non-medical costs 
Only three studies  [27, 31, 32] reported direct non-medical costs.(Table 2) In one study  [27], 
the evaluation included travel costs and other out-of-pocket expenses; they found that these 
costs were much higher in the STRETCH intervention group. In another study  [31] included 
paid help, informal care received by patients and out-of-pocket costs, and found no 
significant difference in direct non-medical costs between groups. Another study  [32] 
included costs associated with self-help groups and relatives’ time and found the direct non-
medical costs for the supportive-experimental group therapy were nearly double the costs of 
cognitive-behavioral group therapy (CBT). 
 
Indirect non-medical costs 
Three studies reported the indirect non-medical costs [27, 31, 32](Table 2). In one 
study  [27], the indirect non-medical costs included patient time, leisure time forgone, loss of 
productivity, and program volunteers; they found the STRETCH intervention group incurred 
the highest indirect non-medical cost. One study  [31] included the costs of lost production in 
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terms of both paid work and domestic tasks, and found that the costs of lost production were 
substantially higher in the hospital follow-up plus educational group program (EGP) and in 
the nurse-led telephone follow-up compared to nurse-led telephone follow-up  plus EGP and 
to usual hospital follow-up. Another study  [32] reported that the costs related to sick leave 
were lower in the cognitive-behavioral group therapy than in the supportive-experimental 
group therapy. 
 
Six of eight studies  [26, 28-32] reported missing data and the statistical methods used to 
adjust for this. Discounting of costs was only relevant for one study that had 2 years of 
follow-up, but this was not applied.  [30]  
 
Drivers of costs 
We analysed the drivers of costs in the included studies. Direct medical costs appeared to be 
the most apparent cost driver. For Gordon et al. the cost of health services expenditures was 
estimated to be 40% of the total cost of the intervention {Gordon, 2005 #182}. The study by 
Sabariego et al.{Sabariego, 2011 #453} reported direct medical cost as the most important 
cost.  For two studies inpatient hospital care {Arving, 2013 #599} and hospitalisation costs 
{Lemieux, 2006 #308} were found to be the drivers of costs. Only one study reported direct 
non medical cost including the cost of lost production as the main cost category {Kimman, 
2011 #1046}. The study by Bares et al.{Bares CB, 2013 #585} reported staffing cost as the 
most important cost category however, they did not include the medical costs. In the contrary 
Mandelblatt et al.{Mandelblatt, 2008 #330} excluded staffing costs and they also reported the 
cost of health care utilisation as the most important costs.  
 Cost of the psychosocial interventions were not considered as drivers  of costs in the studies. 
They were found to be inexpensive compared to the others costs.  
13 
 
 
Outcomes 
Many psychological outcomes were reported by the primary studies, including distress, 
coping style, anxiety, fear of cancer progression, mood, pain, and health functioning. (Table 
2) Four studies [27, 28, 31, 32] reported utility-based health-related quality of life (HRQOL) 
outcomes used in the calculation of QALYs. One study [30] used the EORTC-QLC-C30 
questionnaire to obtain quality of life scores which were then transformed into utilities using 
a published algorithm [34]. One study [27] used the Functional Assessment of Cancer 
Therapy–Breast Cancer scale plus Arm Morbidity scale (FACT-B+4) to measure HRQOL. 
Utility scores were derived using a single–item linear analogue scale. Two studies [28, 31] 
measured HRQOL using the EQ-5D rated at three levels. QALYs for the above three studies 
were generated by multiplying one year of life by the mean utility score for that year. One 
study [32] used the 12-item Health Survey (SF-12) to measure the mental score at 12 months; 
however, they did not use the SF-12 to estimate QALYs.  
 
Cost-effectiveness 
Table 2 summarises the outcomes of the economic evaluations. All eight studies included in 
the review reported incremental cost-effectiveness ratios (ICER). None of the included 
studies applied a discount rate to the outcomes. Four of eight studies reported the ICER per 
QALY gained [27, 28, 30, 31]. Based on the QALY outcome, all of these studies  [27, 28, 30, 
31] reported that psychosocial interventions were cost-effective compared to usual care 
(Table 2).  
 
Five  studies calculated ICERs based on psychological outcomes such as distress, [25, 26] 
number of rehabilitated cases [27], mood, pain [29], fear of cancer progression, and mental 
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score [32] (Table 2). For distress, one study  [25] reported that the psychosocial intervention 
(CBT) was cost-effective in reducing distress, while another  [26] found their most intensive 
intervention arm, counselling + video + booklet, was higher in cost and less effective in 
reducing cancer-specific distress compared to the booklet alone and video alone arms. For the 
outcome of ‘rehabilitated cases’ described as the improvement in the FACT-B+4 score that 
reached minimal clinically meaningful difference (score increase of at least 3.5 points from 6 
to 12 months post-diagnosis), the authors  [27] found that the usual care arm was most 
efficient. Lemieux and colleagues [29] reported an incremental cost of $5,550 per clinical 
improvement in mood and an incremental cost of $4,309 per clinical improvement in pain, 
and the authors considered these costs acceptable compared to usual care [29]. One 
study  [32] found that for both fear of cancer progression and mental score outcomes, the 
cognitive behavioural therapy-based intervention was cost-effective compared to usual care.  
 
Table 3 presents the permutation matrix of the cost-effectiveness results, for both QALYs and 
psychological outcomes. Based on this matrix, six studies favoured psychosocial 
interventions [25, 27, 28, 30-32], one study favoured usual care  [26], and for one study, 
additional incremental analysis would be needed to judge whether the added effect was worth 
the added cost or if the reduced effect was acceptable given reduced cost [29]. Of the six 
favoured psychosocial interventions, three were cognitive behavioural therapy 
interventions  [25, 30, 32] one was a nurse-delivered telephone follow-up plus educational 
group program [31], one was a group based exercise and psychosocial intervention [27] and 
one was 10 individual (face-to-face or telephone) nurse-delivered support sessions  [28] (see 
Table 3).  
 
Quality appraisal 
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Figure 2 displays the quality score for each study using the CHEC-list. The overall quality 
score was combined with the percentage of criteria met. The included studies scored a 
maximum of 17 points out of the 19 on the CHEC-list, with most of the studies meeting more 
than 70% of the 19 criteria. The highest quality score achieved in this study was 89% by 
Kimman et al.{Kimman, 2011 #1046} and  Mandelblatt et al{Mandelblatt, 2008 #330}.. Two 
studies, by Bares (42% of the criteria met) [25] and by Lemieux (53% of the criteria 
met) [29] lacked methodological rigour. In one study  [25], the perspective chosen was not 
stated, not all costs and outcomes were properly identified and valued, and a sensitivity 
analysis was not conducted.  In one study  [29], the research question was not clearly defined 
and some relevant medical costs were not considered (e.g costs related to medical oncologists 
and GP visits). Of the six studies that identified a psychosocial intervention as cost-effective, 
five  [27, 28, 30-32] were classified as good quality, with 74%, 89% and 84% of the criteria 
met, respectively; the sixth study  [25] was classified as low quality (42% of the criteria met). 
The study that rejected the cost-effectiveness of the psychosocial intervention (counselling + 
educational booklets), was of good quality, with 89% of the criteria met [26]. 
 
All studies clearly described their study populations and competing alternatives. In four 
studies the research questions were not clearly stated [25, 28, 30, 31].   
We judged the economic evaluation designs to be appropriate for all of the studies except for 
one study  [29], who performed a cost minimisation analysis where we believed a cost-utility 
analysis would have been more appropriate. All but one study  [25] undertook sensitivity 
analyses to assess the robustness of their findings  [26-32], although at times the details of the 
factors tested were missing.  
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Discussion 
Incremental cost-effectiveness ratios (ICERs) from the studies included in this review 
showed that psychosocial interventions can be a cost-effective approach in cancer care. Six 
studies favoured psychosocial interventions compared to the next best alternative, one study 
favoured usual care, and for one study, incremental analysis would be needed to judge if the 
added effect was worth the added costs or if reduced effect was acceptable given the reduced 
costs. The findings of this review provide us with important information about treatment 
efficiency (i.e. cost-effectiveness) that can guide current policy and clinical practice. For 
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stronger evidence, however, future studies evaluating psychosocial interventions in cancer 
should include full economic evaluations.  
 
Given the variability in the types of psychosocial interventions and alternatives evaluated, we 
could not provide a conclusive recommendation for the most cost-effective type of 
psychosocial intervention for psychological adjustment in cancer patients. Three of the six 
studies that favoured psychosocial interventions had adopted a cognitive behavioural therapy 
approach and two of those interventions were of good methodological quality; however, 
given the small number of available studies and limited selection of theoretical approaches 
captured by these studies, it is not possible to comment on the type of intervention that is 
most cost-effective in this context.  
 
Guidelines have been published to guide the conduct, analysis and reporting of trial based 
economic evaluations [35]. Although the methodological quality of the economic evaluations 
in the eight studies in this review was good overall, there were some methodological flaws. 
First, there was a lack of clearly defined economic questions in most of the studies. A well-
defined health economic question should state the perspective, the comparators, the time 
horizon, and also consider both costs and consequences. Second, only half the studies 
reported QALYs as an outcome. The QALY, which is a preference-based measure of health 
outcome that combines length of life and health-related quality of life, has been reported as 
the preferred outcome measure for many health system funders [35, 36]. The QALY has the 
advantage of enabling comparisons of cost-effectiveness between interventions in different 
health conditions, and for economists, the QALY offers the additional advantage of 
incorporating individual preferences for health states, thereby moving beyond the narrow 
biomedical model for evaluative research [35]. 
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Another important limitation of the studies was that the category costs were narrow in scope. 
Few studies adopted a societal perspective with the costs of lost productivity (i.e. indirect 
non-medical costs) reported by only three studies, despite being an important cost supported 
by the government social welfare. For example, Bradley et al. [37] estimated US cancer-
related productivity losses of $142.4 billion in 2010. A limited focus on direct medical costs 
may result in underestimation of the total economic costs and lead to misleading 
conclusions. The adoption of societal perspective as a norm has been described as necessary 
in order for the economic evaluation to provide the correct incentives for decision makers to 
take into account, for both static and dynamic efficiency, when making decisions about 
allocation of resources for improvement of health {Jonsson, 2009 #3356}. However there is 
controversy around wheter the inclusion of productivity changes constitutes double counting 
and around the equity implications {Drummond MF, 2005 #3291} 
 
 
This review has several strengths. First, we devised a broad search strategy to capture a range 
of psychological outcomes and psychosocial interventions from a comprehensive list of 
electronic databases. Second, to help clinicians and decision makers, we categorised the cost-
effectiveness results in a permutation matrix to clearly indicate which interventions could be 
accepted or rejected on efficiency grounds. Third, we excluded cost consequence analyses, as 
these studies did not present aggregated results in the form of ICER or net benefit. From a 
clinical and policy-makers perspective, it is more helpful to present costs and effectiveness 
results as a single index (ICER), as this allows policy-makers to judge if the combined 
distribution of costs and effects for an intervention is cost-effective at a given willingness to 
pay threshold [36, 38].  
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A limitation of this review is that we did not conduct a search of the grey literature, 
particularly government reports, conference abstracts and unpublished theses, so publication 
bias could not be eliminated. Further, the studies included in this review were from different 
countries with different costs of healthcare and willingness to pay thresholds; therefore, we 
could not pool the results in a meta-analysis, or present all results on a single cost-
effectiveness plane. In addition, In addition, the studies captured in this review varied  
widely in the format and design of interventions  and the description of usual care. Lastly, 
most of the studies were conducted among breast cancer patients and this is likely to affect 
the generalisability of the results to other cancer populations and to men.    
 
Conclusion 
Despite the importance of cost-effectiveness studies for translating study findings into 
clinical practice and policy, there are relatively few cost-effectiveness studies of psychosocial 
interventions for cancer patients and survivors, in the literature. In this review, the emerging 
evidence suggests that offering information, emotional support, and psychological care to 
cancer patients and survivors can be cost-effective. Future studies should ideally evaluate a 
broader range of psychosocial interventions i.e. that use different theoretical approaches, to 
help decide which types of interventions are most cost-effective. Our review demonstrates 
that psychosocial interventions can be efficiently implemented and potentially integrated into 
the health care system as a complement to medical therapies.  
 
The methodological quality of the available studies was relatively good but there is room for 
improvement. A stronger focus on transparency and consistency when reporting the methods 
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and findings of economic evaluations is needed to allow for greater comparisons across 
interventions, and to help clinicians, researchers and policy makers decide which are the most 
appropriate interventions. For better reporting, economic evaluations should clearly state the 
research question, include all costs (both direct and indirect) associated with cancer, and use a 
utility-based measure such as QALYs. Including these important factors in the design and 
reporting of future studies will assist in determining the cost-effectiveness of psychosocial 
interventions for improving health outcomes for people with cancer. Better evidence around 
the cost-effectiveness of psychosocial interventions in cancer will enable policy makers to 
consider economic value, along with clinical efficacy, when making resource allocation 
decisions.  
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Figure 1. Flow chart of study selection 
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Figure 2. Guidance for decision makers based on cost-effectiveness results, presented as a 
permutation matrix 
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The dark orange colour         indicates that the decision is strongly favoured either accepted (box G) or rejected (box C). The 
light orange colour         indicates a situation in which a decision is less favoured either accepted (D and H) or rejected (B 
and F). The  boxes A and J indicates cases in which there is no obvious decision—that is, some form of financial or clinical 
trade off is required or no differences are observed (box E). 
 
Figure 3. Summary appraisal of the methodological quality of the included studies based on 
the 19-item Consensus Health Economic Criteria (CHEC)-list criteria -list criteria. 
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Table 1. Characteristics of included studies  
First author Year Country Type of cancer Population Intervention  Comparator Mean age in years 
/proportion of men and 
women 
Arving C. [30] 
 
 
 
2013 
 
 
 
Sweden 
 
 
 
Breast cancer Consecutive breast 
cancer patients starting 
adjuvant therapy 
(N=168) 
 
 
 
Individual (face to face or telephone) 
cognitive-behavioural therapy based 
psychosocial support to breast cancer 
patients provided by: (1) oncology nurses 
or (2) psychologists. Participants received 
between 0 and 23 support sessions 
depending on needs. 
Usual care included 
contacts with 
medical staf, 
referrals to 
psychiatrist or 
social worker for 
discussion. 
55 (for all groups) 
100% women 
Bares C. [25] 
 
 
 
 
 
 
2002 
 
 
 
 
 
 
USA 
 
 
 
 
 
 
Melanoma 
 
 
 
 
Melanoma patients at the 
multidisciplinary 
melanoma clinic at the 
University of Michigan 
Comprehensive Cancer 
centre. (n=38) 
 
Usual care plus individual cognitive-
behavioural therapy consisted of: (1) 
sessions intended to provide instruction in 
skills acquisition (2) workbook containing 
sections on relaxation training, challenging 
of negative thoughts and problem-solving 
Usual care included 
regular contact 
with the patient’s 
oncologist and 
medical staff. 
Mental health 
services were also 
available as 
needed.  
 
Not reported 
Gordon L. [27] 
 
 
2005 
 
 
Australia 
 
 
Breast cancer Breast cancer survivors 
(N=275) 
 
 
 
 
(1) Home-based physiotherapy 
intervention (DAART)  
(2) 8 sessions Group-based exercise and 
psychosocial support group 
(STRETCH) 
 
Non- intervention 
sample  
59 (group 1) 
54 (group 2) 
55 (Non-intervention) 
100% women 
Kimman M. [31] 
 
 
 
 
 
 
 
 
2011 
 
 
 
 
 
 
 
 
 
The Netherlands 
 
 
 
 
 
 
 
 
 
Breast cancer 
 
 
 
 
 
 
 
 
 
Women who have 
recently (less than 6 
weeks) completed breast 
cancer treatment 
(N=299) 
 
 
 
 
 
(1)Nurse-led telephone follow-up 
comprising a mammography combined 
with an outpatient visit and telephone 
interviews (2)Short educational group 
program + Nurse-led telephone follow-up 
(3)Short educational group program 
+Hospital follow up 
Hospital follow up 
as usual: five 
outpatient clinic 
visits including one 
mammography 
 
56 
100% women 
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Lemieux J. [29] 
 
 
 
 
2006 
 
 
 
 
Canada 
 
 
 
 
Breast cancer Women with metastatic 
breast cancer (N=125) 
 
 
 
 
Weekly supportive-expressive 
psychosocial group (6 to 10 participants) 
therapy and professionally led + usual care 
Usual care alone 
including access to 
necessary 
medical,  surgical, 
or psychosocial 
care. Every four to 
six months, 
educational 
materials about 
breast cancer 
and its treatment, 
as well as about 
relaxation and 
nutrition were 
provided. 
 
49 (intervention) 
52 (control) 
100% women 
Mandelblatt 
J. [26] 
 
 
 
 
2008 
 
USA 
 
 
 
 
Breast cancer 
 
 
 
 
Women completing 
breast cancer treatment 
(N=389) 
 
 
 
(1) Psycho-educational intervention  
comprising of a video support + 
booklet + 2 individual counselling 
session (one face to face and 1 
telephone) 
(2) Booklet + video support 
Booklet alone 58  
100% women 
Sabariego 
C. [32] 
 
 
 
 
 
 
 
 
2011 
 
 
 
 
 
 
 
 
Germany 
 
 
 
 
 
 
 
 
Mixed cancers 
 
 
 
 
 
 
 
 
Cancer patients receiving 
inpatient rehabilitation. 
Breast 59%, colorectal 
8%, bladder/prostate 8%, 
gynaecologic 8% other 
cancer 16% (N = 174) 
 
 
 
Directive  group psychotherapy : 4 
cognitive-behavioural group therapy 
oriented sessions + 3-week inpatient 
rehabilitation program 
 
Non- directive  
group 
psychotherapy : 4 
supportive 
experimental group 
therapy sessions + 
3-week inpatient 
rehabilitation 
program 
54 (Group 1) 
54 (Group 2) 
Group 1: 86% females and 
14% males. Control:86% 
females and 15% males. 
Strong V. [28] 
 
2008 
 
UK 
 
Mixed cancers 
 
Breast 44%, 
gynaecologic 15%, 
Up to 10 (face to face or telephone) nurse 
delivered sessions comprising education 
Usual care 
including free 
57 (same in both groups) 
Intervention: 69% females 
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colon 6%, other cancer 
patients 34% (N = 200) 
 
 
about depression, problem-solving and 
communication with doctors + usual care 
access to treatment 
to depression. 
and 31% males. Control:72% 
females and 28% males 
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Table 2. Summary of economic evaluation methods and results 
First author 
Year 
Type of 
Economic 
Evaluation 
Perspective Time horizon Reference 
year for 
costs 
Currency Categories of 
costs included 
Utility/ 
health 
outcomes 
Psychological 
outcomes 
Incremental cost effectiveness 
ratio (ICER) or incremental net 
benefit (INB) results 
Sensitivity 
analyses/factors 
Arving, 
C. [30]  
2013 
Cost-utility 
analysis 
Health care 
system 
 
2 years 
 
2006 Euro € Direct medical 
costs 
Intervention 
costs 
Quality 
adjusted 
life years 
EORTC-
QLC-C30 
 Both INS IPS dominated the 
Usual care  
Cost: INS=€18670, 
IPS=€20419, Usual care 
=€25800 
QALYs: INS=1.52QALY, 
IPS=1.59QALY and Usual care 
=1.43QALY. 
 
Several one-way 
sensitivity 
analyses/ QALY 
calculations, tumor 
size, lymph node 
metastases, number 
of support sessions 
 
Bares, C. [25] 
2002 
Cost-
effectiveness 
analysis 
Health care 
system 
 
1 year 
 
 
 
 
 
Not 
specified 
USD $ Direct medical 
costs 
Intervention 
costs  
- Distress, coping 
style, anxiety 
and health 
functioning 
Global Severity 
Index of the 
BSI was used. 
 
 
ICER for Usual care =$402.37 
for 1 point decrease of the GSI 
score, ICER for Usual care 
+cognitive behavioural 
therapy=$7.66 for 1 point 
decrease of the GSI score 
Not reported 
Gordon, 
L. [27] 
2005 
Cost-
effectiveness 
analysis 
Societal 
 
1 year 
 
 
 
 
 
 
2004 AUD $ Direct medical 
costs, Direct 
non-medical 
costs, Indirect 
non-medical 
costs 
 
Quality 
adjusted 
life years 
FACT-
B+4 
Rehabilitated 
cases=clinical 
improvement 
based on 
FACT_B+4 
scores 
 
DAART: ICER= $2217 per 
rehabilitated case; STRETCH: 
ICER =$31367 per 
rehabilitated case; ICER for the 
non intervention group was 
negative. The non intervention 
group dominated. 
 
The ICER for DAART was 
AU$1344 per QALY gained 
and AU$14478 per QALY 
gained for the STRETCH. The 
non intervention group 
dominated. 
Several one-way 
sensitivity analyses 
and a probabilistic 
sensitivity 
analysis/cost, 
utility scores, 
probability of 
rehabilitated cases. 
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Kimman, 
M. [31] 2011 
Cost-
effectiveness 
analysis 
Societal 1 year 
 
 
 
2008 Euro € Direct medical 
costs, Direct 
non-medical 
costs, Indirect 
non-medical 
costs 
 
Quality 
adjusted 
life years 
EQ-5D  
(level 3) 
 Hospital follow up 
+educational group program 
yielded an ICER of € 235 per 
QALY gained and was 
dominated by the Telephone 
follow up +educational group 
program 
 
Several one-way 
sensitivity 
analyses/unit prices 
of telephone 
contacts and 
hospital visits; the 
highest reported 
duration of 
telephone call and 
the generic cost 
price for a hospital 
visit; the use of 
Dutch EQ-5D tariff 
for utility scores. 
 
 
Lemieux, 
J. [29] 
2006 
Cost-
minimisation 
analysis and 
Cost-
effectiveness 
analysis 
Health care 
system 
 
1 year 
 
 
 
 
 
 
  
2002/2003 CAN $ Direct medical 
costs 
Intervention 
costs 
Survival, 
mood, 
pain  
POMS 
Mood and pain 
POMS 
Incremental cost of $5550 for 
an effect of 0.5 for mood and 
an incremental cost of $4309 
for an effect size of 0.5 for 
pain.  
One-way and two-
way sensitivity 
analysis/ total cost; 
hospitalisation 
costs calculations 
methods; total cost 
estimates for a 
range of ±20%; 
benefit of mood 
and pain using 
different effects 
(small, medium, 
large). 
Mandelblatt, 
J. [26] 2008 
Cost-
effectiveness 
analysis 
Societal 1 year 2002 USD $ Direct medical 
costs (excluding 
medications 
- Distress and 
vitality 
IES-R, MOS 
The most intensive 
intervention, 
counselling+video+booklet 
one-way sensitivity 
analysis/cost and 
effect of 
31 
 
 
 
 
 
costs) 
Intervention 
costs 
SF-36 was higher in cost and lower in 
change in distress. Video + 
NCI booklet dominated the 
other with an ICER of $7275 
per change in cancer specific 
distress for all women. For 
women with high preparedness 
counselling + video + booklet 
ICER of $1066 per change in 
cancer specific distress. 
counselling. 
Sabriego, 
C. [32] 2011 
Cost-
effectiveness 
analysis 
Societal 1 year 
 
 
 
2004 Euro € Direct medical 
costs, Direct 
non-medical 
costs, Indirect 
non-medical 
costs 
 
 
Mental 
score (SF-
12) 
Fear of 
progression 
(Fear of 
Progression 
Questionnaire), 
mental 
component 
score (SF-12) 
Cognitive behavioural therapy 
was the dominant strategy with 
an ICER of minus €78741 for 
an additional reduction of fear 
of progression; 
ICER of minus €16975 for an 
additional improved mental 
score. 
 
Presented 
confidence 
intervals from 
bootstrap and 
acceptability 
curves from the 
ICERs 
Strong, 
V. [28]  
2008 
Cost-utility 
analysis 
 
 
 
 
Health care 
system 
 
1 year 
 
 
 
 
 
2006 Pounds £ Direct medical 
costs (excluding 
cancer treatment 
costs) 
Intervention 
costs 
Quality 
adjusted 
life years 
 EORTC-
QLC-C30, 
EQ-5D 
(level 3). 
Depression 
(SCL-20, DSM-
IV), anxiety 
(SCL-90) 
The ICER for the intervention 
was £5278 per QALY gained. 
The intervention dominated. 
Simple one-way 
sensitivity 
analysis/confidence 
interval of the costs 
and effects. 
DAART = Domiciliary allied and acute care rehabilitation team, STRETCH = Strength through recreation exercise togetherness care health, EORTC-QLC-C30 = European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire, EQ-5D = Euro Quality of Life -5-Dimensional Classification, INS = individual nurse support, IPS = individual psychologist support, DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition, SCL-20 = Symptom Checklist Depression Scale - 20-item, IES-R = Revised Impact of Events Scale, MOS = Medical Outcomes Study, SF-36 = Short Form, POMS = Profile of Mood States, NCI = National Cancer Institute, 
FACT-B+4 = Functional Assessment of Cancer Therapy –Breast Cancer plus arm morbidity scale. BSI = Brief Symptom Inventory, GSI = Global Severity Index.
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Table 3: Summary appraisal of the methodological quality of the included studies based 
on the 19-item Consensus Health Economic Criteria (CHEC)-list criteria -list criteria. 
Study Number of criteria met 
N (%) 
Kimman et al. 2011 17 (89%) 
Mandelblatt et al.  2008 17 (89%) 
Sabariego et al.  2011 16 (84%) 
Arving et al. 2013 14 (74%) 
Gordon et al. 2005 14 (74%) 
Strong et al. 2008 14 (74%) 
Lemieux et al. 2006 10 (53%) 
Bares et al.  2002 8 (42%) 
 
 
                                   
